The research team at the College of Life Sciences at Dundee University have been studying the tumour suppressor protein PTEN, which is `turned off’ or damaged in many cancers.
 Dr Nick Leslie |
Brain tumours are particularly deadly, having a very poor prognosis, because although they rarely spread outside the brain, by the time they are diagnosed, some cancer cells have usually developed away from the original tumour and infiltrated the surrounding brain tissue. Therefore, when a surgeon removes the initial tumour, it is often not long before a second tumour grows from the few cancer cells in the surrounding brain tissue.
Dr Leslie’s team set up experiments, using a 3D matrix similar to that found between cells in the brain, to investigate this process of how cancer cells invade from a tumour mass into healthy tissue. Their work, published in the journalScience Signalling, describes how PTEN controls the way these brain tumour cells grow, change their shape, switch particular genes on and off and importantly how PTEN normally stops this invasion process.
“We know that PTEN has lots of effects on what cells do, but it has proved harder to be certain which of these effects are most important in stopping cancer and therefore which ones we should develop drugs to target,” said Dr Leslie. “We already know a lot about one way in which PTEN can stop cells growing and dividing, but there have been several hints in the past that there are other undiscovered ways in which PTEN may stop cancers developing.
“In our new work, we’ve used two similarly damaged versions of PTEN, one of which was found in a tumour, that we show can still do the best recognised things that PTEN does, just as well as normal PTEN protein. However, these damaged proteins have completely lost the ability to stop brain tumours cells invading through a 3D matrix. This implies that in some, and perhaps many, tumours it is poorly understood mechanisms and the control of processes that include invasion which explain why PTEN gets damaged.
“The work also identified a ‘gene signature’ (showing which genes are turned on and off in particular cells) that is controlled by PTEN, which links to its control of invasion, but not its best recognised ways of working.
Interestingly this gene signature also seemed to be recognisable in almost all of a large set of human brain tumour samples that lack PTEN, providing more evidence that this new way in which PTEN works may be important in brain tumour development. The key goals of future work in this area need to include understanding much more about these new ways in which PTEN can work and whether they show us new ways to develop drugs to treat brain and other tumours.”
The work of Dr Leslie and the Dundee team has also been supported by funding from the Medical Research Council.
